Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability - PubMed (original) (raw)
Comparative Study
Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability
Bibo Yuan et al. Clin Cancer Res. 2006.
Abstract
Purpose: Most breast cancers have chromosomal instability that seems related to defective mitotic spindle checkpoints. Because the molecular basis of this defect is unknown, we evaluated breast cancer cell lines and tissues for possible defects involving the major mitotic checkpoint genes responsible for maintaining chromosomal stability.
Experimental design: We analyzed sequences and expression levels (RNA and protein) of eight major spindle checkpoint genes (MAD1L1, MAD2L1, MAD2L2, BUB1, BUB1B, BUB3, CDC20, and TTK) in a panel of 12 breast cancer cell lines, most with established genetic instability and defective spindle damage checkpoint response. mRNA levels of these genes were also measured in primary tumor samples, and immunohistochemical staining was used to evaluate BUB1B protein levels in a panel of 270 additional cases of breast cancer.
Results: No functionally significant sequence variations were found for any of the eight genes in the breast cancer cell lines with chromosomal instability. More surprisingly, the mRNA and protein levels for these checkpoint genes are significantly higher in the genetically unstable breast cancer cell lines and in high-grade primary breast cancer tissues than in the stable (and checkpoint proficient) MCF-10A and normal mammary epithelial cells, or in normal breast tissues. In fact, overexpression of the BUB1B protein is a marker that recognizes nearly 80% of breast cancers in paraffin-embedded tissues.
Conclusions: Defective mitotic spindle checkpoints in breast cancer are most likely not caused by low expression or mutations of these eight checkpoint genes. High levels of these particular transcripts could represent a cellular compensation for defects in other molecular components of the mitotic spindle damage checkpoint, and increased expression of these genes might be markers of breast cancers with chromosomal instability.
Similar articles
- Overexpression of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in gastric cancer--association with tumour cell proliferation.
Grabsch H, Takeno S, Parsons WJ, Pomjanski N, Boecking A, Gabbert HE, Mueller W. Grabsch H, et al. J Pathol. 2003 May;200(1):16-22. doi: 10.1002/path.1324. J Pathol. 2003. PMID: 12692836 - A double missense variation of the BUB1 gene and a defective mitotic spindle checkpoint in the pancreatic cancer cell line Hs766T.
Hempen PM, Kurpad H, Calhoun ES, Abraham S, Kern SE. Hempen PM, et al. Hum Mutat. 2003 Apr;21(4):445. doi: 10.1002/humu.9120. Hum Mutat. 2003. PMID: 12655561 - Breast cancer risk associated with genotypic polymorphism of the mitotic checkpoint genes: a multigenic study on cancer susceptibility.
Lo YL, Yu JC, Chen ST, Hsu GC, Mau YC, Yang SL, Wu PE, Shen CY. Lo YL, et al. Carcinogenesis. 2007 May;28(5):1079-86. doi: 10.1093/carcin/bgl256. Epub 2007 Jan 8. Carcinogenesis. 2007. PMID: 17210994 - The mitotic checkpoint in cancer and aging: what have mice taught us?
Baker DJ, Chen J, van Deursen JM. Baker DJ, et al. Curr Opin Cell Biol. 2005 Dec;17(6):583-9. doi: 10.1016/j.ceb.2005.09.011. Epub 2005 Oct 13. Curr Opin Cell Biol. 2005. PMID: 16226453 Review. - The spindle checkpoint: from normal cell division to tumorigenesis.
Lopes CS, Sunkel CE. Lopes CS, et al. Arch Med Res. 2003 May-Jun;34(3):155-65. doi: 10.1016/S0188-4409(03)00024-9. Arch Med Res. 2003. PMID: 14567393 Review.
Cited by
- BUB1 immunolocalization in breast carcinoma: its nuclear localization as a potent prognostic factor of the patients.
Takagi K, Miki Y, Shibahara Y, Nakamura Y, Ebata A, Watanabe M, Ishida T, Sasano H, Suzuki T. Takagi K, et al. Horm Cancer. 2013 Apr;4(2):92-102. doi: 10.1007/s12672-012-0130-x. Epub 2013 Jan 4. Horm Cancer. 2013. PMID: 23288590 Free PMC article. - Overexpression of BUB1B contributes to progression of prostate cancer and predicts poor outcome in patients with prostate cancer.
Fu X, Chen G, Cai ZD, Wang C, Liu ZZ, Lin ZY, Wu YD, Liang YX, Han ZD, Liu JC, Zhong WD. Fu X, et al. Onco Targets Ther. 2016 Apr 15;9:2211-20. doi: 10.2147/OTT.S101994. eCollection 2016. Onco Targets Ther. 2016. PMID: 27143916 Free PMC article. - Identification of candidate genes associated with the pathogenesis of small cell lung cancer via integrated bioinformatics analysis.
Liao Y, Yin G, Wang X, Zhong P, Fan X, Huang C. Liao Y, et al. Oncol Lett. 2019 Oct;18(4):3723-3733. doi: 10.3892/ol.2019.10685. Epub 2019 Jul 29. Oncol Lett. 2019. PMID: 31516585 Free PMC article. - Targeting the cell cycle in breast cancer: towards the next phase.
Thu KL, Soria-Bretones I, Mak TW, Cescon DW. Thu KL, et al. Cell Cycle. 2018;17(15):1871-1885. doi: 10.1080/15384101.2018.1502567. Epub 2018 Sep 11. Cell Cycle. 2018. PMID: 30078354 Free PMC article. Review. - The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC.
Marwitz S, Turkowski K, Nitschkowski D, Weigert A, Brandenburg J, Reiling N, Thomas M, Reck M, Drömann D, Seeger W, Rabe KF, Savai R, Goldmann T. Marwitz S, et al. Front Oncol. 2020 Jan 21;9:1550. doi: 10.3389/fonc.2019.01550. eCollection 2019. Front Oncol. 2020. PMID: 32039023 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous